The earnings call highlighted strong financial performance with significant improvements in revenue, adjusted EBITDA, and gross margins. Successful product launches and strategic debt restructuring were positive. However, challenges remain with declining device revenue, regional revenue declines, and increased churn. The macroeconomic environment and seasonal factors are expected to impact the next quarter.

Company Guidance -

Q3 2025

During The Beauty Health Company's second quarter 2025 earnings call, the company reported exceeding both revenue and adjusted EBITDA guidance for the third consecutive quarter. Q2 revenue reached $78.2 million, with adjusted EBITDA of $13.9 million, surpassing expectations. The gross margin improved to 62.8% GAAP and 65.9% adjusted. The company's consumables, now over 70% of total revenue, demonstrated strength, highlighting the success of their razor-razor blade model. The quarter saw a launch of HydraFillic with Pep9 booster, their top-performing HydraFacial booster, alongside an expansion to over 35,000 active devices globally. Operating expenses were reduced by nearly 18%, and the company closed the quarter with $212 million in cash. Despite macroeconomic headwinds affecting device sales, the company remains confident in their long-term strategy, supported by a strengthened sales organization and a new Chief Revenue Officer. For fiscal 2025, revenue guidance was raised to $285-$300 million, with adjusted EBITDA expected to be between $27-$35 million.

Exceeded Revenue and Adjusted EBITDA Guidance

The Beauty Health Company exceeded both revenue and adjusted EBITDA guidance for the third consecutive quarter, driven by consumables revenue, margin expansion, and operational improvements.

Significant Gross Margin Improvement

Gross margin improved significantly with GAAP at 62.8% and adjusted at 65.9% for the quarter.

Successful Product Launches

The HydraFillic with Pep9 booster became the top-performing HydraFacial branded booster, contributing to booster sales growth in the Americas by over 8% year-on-year.

Debt Restructuring

The company restructured its debt, which included a convertible note exchange, extending the debt maturity profile and enhancing long-term financial flexibility.

Provider and Market Expansion

The company expanded to over 35,000 active devices globally, showing growth from 33,500 last year. There was also double-digit growth in consumables in EMEA.

Cash Position

The company closed the quarter with $212 million in cash following strategic debt restructuring.

Beauty Health (SKIN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SKIN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.07 / -	-0.15	―	―	―
Aug 07, 2025	2025 (Q2)	-0.05 / 0.16	-0.057	380.70% (+0.22)
May 08, 2025	2025 (Q1)	-0.13 / -0.08	-0.01	-700.00% (-0.07)
Mar 12, 2025	2024 (Q4)	-0.11 / -0.08	-0.028	-185.71% (-0.05)
Nov 12, 2024	2024 (Q3)	-0.09 / -0.15	-0.5	70.00% (+0.35)	―
Aug 08, 2024	2024 (Q2)	-0.01 / -0.06	0.061	-193.44% (-0.12)	―
May 09, 2024	2024 (Q1)	-0.10 / -0.01	-0.042	76.19% (+0.03)	―
Mar 12, 2024	2023 (Q4)	-0.07 / -0.03	0.056	-150.00% (-0.08)	―
Nov 13, 2023	2023 (Q3)	0.07 / -0.50	0.052	-1061.54% (-0.55)	―
Aug 09, 2023	2023 (Q2)	0.05 / 0.06	0.012	408.33% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SKIN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$1.59	$1.89	+18.87%
May 08, 2025	$1.24	$1.87	+50.81%
Mar 12, 2025	$1.42	$1.34	-5.63%
Nov 12, 2024	$1.70	$1.85	+8.82%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.